Allos CEO resigns
Executive Summary
Allos Therapeutics CEO and CFO Michael Hart will resign his positions following appointment of a successor CEO. During Hart's tenure, Allos received an "approvable" letter for Efaproxyn (efaproxiral) for use as an adjunct to whole brain radiation therapy for the treatment of brain metastases from breast cancer (1"The Pink Sheet" June 7, 2004, p. 6). Hart joined Allos in 1999 as chief financial officer and senior VP-operations. He was promoted to president and CEO in December 2001, and appointed to the board of directors in April 2002...
You may also be interested in...
Allos Oncologic Efaproxiral Is “Approvable” Pending Phase III ENRICH Data
Approval of Allos' oncologic efaproxiral will need to await positive data from an ongoing Phase III study in patients with brain metastases originating from breast cancer, an FDA "approvable" letter states
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.